HONG KONG DRUG LICENSING

Hong Kong Drug Licence FAQs

Search 500 Hong Kong drug licence FAQs on applications, personnel, premises, quality systems, ongoing regulation, renewals and acquisitions.

Information status: The original FAQ material dates from 2025 and is provided for topic-based reference; it does not represent an individual verification of all 500 FAQs against current rules. For application, fee, renewal, change, product or prescription requirements, please refer to the current official forms and guidance.

Official information from the Drug Office Official information from the Chinese Medicines Board

找到 5 条结果，第 1／1 页。每页显示 20 条；无需启用 JavaScript。

Thematic illustration for pharmaceutical licensing business queries and document organisation services — Discuss actual operating questions one-to-one to clarify the next decision.

Q41 · 香港的药牌可以转让或许可给第三方使用吗？独立链接

No. Hong Kong pharmacy and poisons licences are non-transferable. A licence is issued to a specific applicant (an individual or company) and is linked to the specific premises, key personnel and Quality Management System submitted with the application. The regulatory authority’s decision is based on an assessment of the overall compliance capability of that specific applicant. Therefore, if a company holding a pharmaceutical licence is acquired by another company, or a pharmacy business is sold to a new operator, the new owner or operator must submit a completely new licence application to the regulatory authority in its own name. It must demonstrate that it can also meet all statutory requirements. The old licence ceases to be valid when the business changes hands. Similarly, a licence holder must not “licence” or “lend” its licence to a third party to operate a medicines business in the third party’s name; this is a serious violation.

📘 Regulatory basis

The non-transferability of licences is a fundamental principle of Hong Kong’s licensing system, reflected in the Pharmacy and Poisons Ordinance and the terms under which relevant licences are issued. Any change in business ownership is regarded as requiring a new licence assessment.

📗 Drew Tang's recommendations

For any M&A or asset sale involving a licensed business, an application for a new licence must be made a condition precedent to completion. The buyer should conduct thorough compliance due diligence and allow sufficient time (usually several months) to complete the new licence application process.

📕 Risk notice

Any attempt to circumvent the principle that a licence is not transferable by using complex corporate structures or nominee agreements may be detected by the regulator and treated as fraud. If discovered, not only will the new business be unable to operate lawfully, but the individuals and companies involved may also be blacklisted.

Q96 · 如果我计划收购一家已经持有药物牌照的公司，我需要注意什么？牌照会自动转移给我吗？独立链接

Acquiring an already licensed company is an effective way to enter the market quickly, but the process requires great care. A pharmaceutical licence is granted to a specific company to operate at a specific address; it does not “automatically” transfer or remain valid when the company’s shares change hands. If the company’s ownership (shareholders) or control (directors) changes materially, you must formally notify the licensing authority. The authority will reassess the background and capabilities of the new shareholders and management to decide whether the licence may remain valid under the new ownership. This process may involve submitting extensive documentation and even undergoing a further on-site inspection.

📘 Regulatory basis

Although there is no such thing as a “licence transfer”, the Pharmacy and Poisons Regulations require changes of company directors or partners to be declared. The regulator is entitled to reassess the suitability of the licence in light of the new persons in control.

📗 Drew Tang's recommendations

Before signing any acquisition agreement, we strongly recommend commissioning us to conduct comprehensive compliance due diligence on the target company. We will thoroughly review its licence history, inspection reports, QMS documents, inventory and sales records to identify any potential undisclosed compliance risks or legacy issues. This can help you avoid discovering only after the acquisition that you have taken over a ‘mess’.

📕 Risk notice

The greatest risk is “hidden liabilities”. If the target company committed serious breaches before the acquisition that have not been discovered, you, as the new owner, may face the corresponding legal consequences if they come to light after you take over, including fines or even revocation of the licence. Due diligence is the only way to mitigate this risk.

Q143 · 如果持有药品牌照的公司发生了重大的股权变更，例如被另一家公司收购，是否需要重新申请牌照？独立链接

This depends on the circumstances, but a completely new application is generally not required; instead, strict notification and approval procedures must be followed. When a licensed company undergoes a major shareholding change or transfer of control, the legally licensed entity (that is, the company as a legal person) remains unchanged, so the licence itself remains valid. However, the company must immediately notify the Drug Office, Department of Health, in writing of this major change. The new major shareholders, directors and ultimate beneficial owners must submit their personal particulars to the Pharmacy and Poisons Board (PPB) and undergo a “fit and proper person” assessment. The PPB must be satisfied that, under the new control, the company can and will continue to comply with all licence conditions. In some cases, if the PPB has concerns about the new shareholders’ background or intentions, it may impose additional licence conditions or conduct inspections more frequently.

📘 Regulatory basis

Licence conditions generally require notification to the regulator of any significant change that may affect the company’s control. This is to ensure that the PPB can continue to discharge its statutory duty to supervise the ‘fitness’ of licence holders.

📗 Drew Tang's recommendations

Before any merger and acquisition or major share transaction, we strongly recommend that both buyer and seller make regulatory approval one of the key conditions precedent to completion. We will help the new shareholders prepare the full set of notification documents and proactively communicate with the Drug Office to explain the commercial rationale for the transaction and the future operating plan, with a view to securing a smooth approval process.

📕 Risk notice

“Act first and notify later”—that is, notifying the regulator only after completing a share transaction—is an extremely wrong and dangerous approach. It may be seen as disregard for regulatory requirements and could seriously call into question the integrity of the new management. In the worst-case scenario, if a new shareholder is found not to be a “Fit and Proper Person”, the PPB has the power to initiate licence revocation proceedings.

Q270 · 如果我通过收购一家现有持牌公司来进入市场，其财务成本与从零申请相比如何？独立链接

Acquiring an existing licensed company is a common ‘capital in exchange for time’ strategy, and its financial costs differ considerably from applying from scratch. The main acquisition cost is the ‘share transfer price’, which is usually much higher than the start-up capital required for a new business because it includes the value of the licence-holding company, goodwill in the existing business, its customer network and staff team, and potentially its inventory. By contrast, applying from scratch mainly involves capital expenditure. The advantage of an acquisition is that operations can begin immediately, avoiding the long application and waiting periods. The drawbacks are a large upfront lump-sum investment and the need to conduct thorough due diligence on the target company.

📘 Regulatory basis

After a company’s shareholding changes, although the licence holder remains unchanged, the company will generally need to notify the Department of Health or the Chinese Medicines Board of changes to directors, shareholders and key personnel. A reassessment may also be required to ensure that the new management is likewise qualified to operate.

📗 Drew Tang's recommendations

Before deciding to acquire the company, you must engage a professional team such as us, together with lawyers and accountants, to conduct comprehensive due diligence on the target company. This must cover its financial position, tax compliance, any pending legal proceedings and, most importantly, its compliance record. An apparently cheap ‘shell’ may conceal substantial debts or a troubled compliance history.

📕 Risk notice

The greatest risk is acquiring a company with “hidden problems”. If the target company has a history of serious non-compliance or undiscovered debts, these “legacy liabilities” will pass to you once the acquisition is completed. Gaps in due diligence may mean that what you buy is not assets, but liabilities and endless problems.

Q425 · 如果我的公司被另一家公司收购，我的药品牌照会自动转移给收购方吗？独立链接

No. A pharmaceutical licence is not transferable. A licence is granted to the legal entity that made the original application (that is, your company). If your company is acquired, there are usually two scenarios. The first is a share acquisition: the purchaser buys shares in your company, which remains the same legal entity, although its shareholders change. In this case, the licence remains with your company, but you must notify the regulatory authority of changes to directors and shareholders as required. The second is an asset acquisition: the purchaser buys only the business assets (such as stock and equipment) and operates through its own company. In this case, the purchaser must apply for an entirely new licence in the name of its own company.

📘 Regulatory basis

Both the Pharmacy and Poisons Ordinance and the Chinese Medicine Ordinance establish the principle that licences are non-transferable. A licence is tied to a specific licensee and licensed premises.

📗 Drew Tang's recommendations

Licence issues must be a central consideration in any M&A transaction. Rengangyongsheng (Hong Kong) Limited has provided compliance due diligence and post-transaction integration advice for numerous M&A cases, helping to ensure a smooth transition or reapplication for the licence.

📕 Risk notice

It is a major misconception to think that a licence can be “bought and sold” along with a business. If the acquiring company takes over operations without first obtaining a new licence, it will be operating without a licence, with very serious consequences.

Hong Kong Drug Licence FAQs

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang